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Abstract
Objectives Whole-body MRI (WB-MRI) is recommended by the International Myeloma Working Group for all patients with
asymptomatic myeloma and solitary plasmacytoma and by the UK NICE guidance for all patients with suspected myeloma.
Some centres unable to offer WB-MRI offer low-dose whole-body CT (WB-CT). There are no studies comparing interobserver
agreement and disease detection of contemporary WB-MRI (anatomical imaging and DWI) versus WB-CT. Our primary aim is
to compare the interobserver agreement between WB-CT and WB-MRI in the diagnosis of myeloma.
Methods Consecutive patients with newly diagnosedmyeloma imagedwithWB-MRI andWB-CTwere prospectively reviewed.
For each body region and modality, two experienced and two junior radiologists scored disease burden with final scores by
consensus. Intraclass correlation coefficients (ICC), median scores, Wilcoxon signed-rank test and Spearman’s correlation
coefficients were calculated.
Results There was no significant difference in overall observer scores betweenWB-MRI andWB-CT (p = 0.87). For experienced
observers, interobserver agreement for WB-MRI was superior to WB-CT overall and for each region, without overlap in whole-
skeleton confidence intervals (ICC 0.98 versus 0.77, 95%CI 0.96–0.99 versus 0.45–0.91). For inexperienced observers, although
there is a trend for a better interobserver score for the whole skeleton onWB-MRI (ICC 0.95, 95%CI 0.72–0.98) than onWB-CT
(ICC 0.72, 95%CI 0.34–0.88), the confidence intervals overlap.
Conclusions WB-MRI offers excellent interobserver agreement which is superior to WB-CT for experienced observers.
Although the overall burden was similar across both modalities, patients with lower disease burdens where MRI could be
advantageous are not included in this series.
Key Points
• Whole-body MRI is recommended by the International Myeloma Working Group for patients with multiple myeloma and
solitary plasmacytoma and by the NICE guidance for those with suspected multiple myeloma.
• Some centres unable to offer whole-body MRI (WB-MRI) offer low-dose whole-body CT (WB-CT).
• This prospective study demonstrates that contemporary WB-MRI (with anatomical sequences and DWI) provides better
interobserver agreement in assessing myeloma disease burden for the whole skeleton and across any individual body region
in myeloma patients when compared with low-dose whole-body CT.
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Radiographic skeletal survey (SS), which has been in wide-
spread use for decades, only offers a very crude assessment of
bone involvement in multiple myeloma. More recently, some
centres have replaced skeletal survey with low-dose whole-
body CT (WB-CT), which has been shown to have greater
sensitivity [1–3]. However, because both skeletal survey and
CT predominantly detect the destructive and/or reactive ef-
fects of myeloma disease on trabecular and cortical bone rath-
er than disease within the bonemarrow space, the sensitivity is
inherently limited [4, 5]. The excellent soft tissue contrast of
whole-body MRI (WB-MRI) allows direct imaging of the
bone marrow, resulting in higher sensitivity and earlier detec-
tion. More recently, the superiority of WB-MRI over FDG
PET-CT for disease detection has been demonstrated [6–8].
Consequently, the International Myeloma Working Group
(IMWG) recommends WB-MRI for all patients with
suspected solitary plasmacytoma or asymptomatic myeloma
[9] and in the UK, the National Institute for Clinical
Excellence [10] recommends WB-MRI for all patients with
a suspected new diagnosis of myeloma.
A cost-effectiveness analysis of imaging strategies for my-
eloma diagnosis has reported that WB-CT and WB-MRI give
the highest incremental net monetary benefit (INMB) under
differing prevalence levels when compared with skeletal sur-
vey. Perhaps surprisingly, a negative INMB was reported for
FDG PET-CT [11]. This suggests an approach using either
WB-CTorWB-MRI could be cost-saving and health-improv-
ing. However, there is evidence that WB-CT has a lower le-
sion detection rate and understages patients compared with
WB-MRI using conventional T1-weighted spin-echo and
STIR MR sequences [5]. This margin of superiority is likely
to be further improved with the addition of DWI, which is
superior to conventional MRI sequences for detecting focal
marrow lesions [12]. Nonetheless, as WB-CT is inexpensive
and relatively quick to perform, many centres limited by MRI
capacity may gravitate towards using non-contrast-enhanced
WB-CT as standard imaging in this patient cohort.
However, sensitivity forms only part of the assessment of a
diagnostic test. Diagnostic assessment tools for clinical or re-
search applications must also be reliable. One of the measures
of reliability is the interobserver agreement. To date, the inter-
observer agreement for WB-MRI and WB-CT is unknown in
the context of disease detection in myeloma. Hence, the pri-
mary aim of this study is to compare the interobserver agree-
ment and diagnostic sensitivity for disease detection of WB-
MRI and WB-CT in patients with multiple myeloma.
Materials and methods
Study design and population
The study design was a prospective observational diagnostic
test accuracy study, approved by the institutional review
board. Patients with an established new diagnosis of myeloma
as per IMWG criteria [9] who were planned to be imaged with
bothWB-CTandWB-MRI examinations before starting treat-
ment between 2013 and 2017 were prospectively included
following written informed consent. Patients with second ma-
lignancies were excluded.
Image acquisition
Low-doseWB-CT (mean radiation dose 5 mSv) was acquired
with a 128-slice CT scanner (Somatom Definition Flash,
Siemens Healthineers), 120 kV, 50 mAs, and 0.5-s pitch.
Axial images were reconstructed to 3 mm for review. All
subjects were scanned supine with arms by their sides and
the images were acquired from the skull vertex to the toes.
No intravenous iodinated contrast was administered. Axial
images of 1-mm slice thickness were reconstructed to second-
ary coronal and sagittal images for review. Axial images for
bone and soft tissue assessment were reconstructed from the
raw data obtained during scanning: for bone assessment using
sharp (B50f) kernel and for soft tissue assessment using soft
(B20f) kernel. Secondary coronal and sagittal reconstructions
were generated using a slice thickness of 2 mm and slice
increment of 1.5 mm. The typical duration for WB-CT exam-
ination was less than 5 min. The dose-length products (DLP)
for the WB-CT examinations were recorded.
WB-MRI studies were performed using an Avanto 1.5-T
system (Siemens Healthineers). All subjects were scanned su-
pine with arms by their sides. Coil elements were positioned
from the skull vertex to the knees. Sagittal T1-weighted im-
ages (TR 590 ms, TE 11 ms, FOV 400 mm, slice thickness
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4 mm) and T2-weighted images (TR 2690 ms, TE 93 ms,
FOV 400 mm, slice thickness 4 mm) of the spine were ac-
quired, followed by axial diffusion-weighted sequences (sin-
gle-shot double spin-echo echo-planar technique with STIR
fat suppression in free breathing) using b values of 50 and
900 s/mm2 applied in 3 orthogonal directions and combined
to the isotropic trace images. Diffusion-weighted images were
acquired in multiple contiguous stations of 50 slices per sta-
tion (slice thickness 5 mm, no gap, FOV 430 mm, phase
direction AP, parallel imaging (GRAPPA) factor 2, TR
14800 ms, TE 66 ms, inversion time (TI) 180 ms, voxel size
2.9 mm× 2.9 mm× 5 mm, number of signal averages 4, ma-
trix 150 × 150, bandwidth 1960 Hz per pixel). Axial T1-
weighted Vibe Dixon 3D gradient echo breath-hold sequences
(52 slices per slab, FOV 470 mm, TR/TE 7/2.38, 4.76 ms, flip
angle 30, matrix 192 × 192) were also acquired, matching the
acquisition stacks and partition thickness to the DWI. No in-
travenous gadolinium contrast was used. The typical duration
for WB-MRI examination was 45 min.
Image analysis
For each body region (skull, cervical spine, thoracic spine,
lumbar spine, pelvis, ribs/other, long bones), two radiologists
each with > 10 years of experience, blinded to clinical infor-
mation and theMRI findings, made a categorisation of disease
burden onWB-CTwith a previously described scoring system
[4, 13]. This allowed the assessment of the number of lesions
(> 20, 10–20, < 10, 0) and largest lesion dimension (> 10, 5–
10, < 5, 0 mm) for each body region, assigning a score from 3
to 0 for each characteristic (lesion number and size), i.e. score
3 for > 20 lesions, score 2 for 10–20 lesions, score 1 for < 10
lesions and score 0 for 0 lesions; score 3 for > 10 mm, score 2
for 5–10 mm, score 1 for < 5 mm and score 0 for 0 lesions.
The maximum lesion dimension was measured on the win-
dow setting in which the lesion was the most readily appreci-
ated. A total score was then calculated for the whole skeleton.
To achieve the final observer scores, discrepancies were re-
solved by a consensus reading facilitated by a third experi-
enced radiologist. At a different time, the image reading was
repeated for the WB-MRI data with readers blinded to the
clinical information and CT findings. The maximum lesion
dimension was measured on the sequence in which the lesion
was the most readily appreciated. The image reading for WB-
CT and WB-MRI was subsequently repeated by another pair
of junior radiologists (< 1-year experience as a consultant).
Statistical analysis
Intraclass correlation coefficient (ICC) estimates and their
95% confidence intervals (95%CI) were calculated using a
two-way random absolute single measures model.
Table 1 Interobserver agreement
as demonstrated by intraclass
correlation coefficient (ICC) for
scoring WB-CT for individual
body regions and the whole
skeleton
WB-CT ICC between experienced observers
(95% confidence interval)
ICC between junior observers
(95% confidence interval)
Cervical spine 0.42 (0.04–0.70) 0.36 (scale not reliable–0.72)
Thoracic spine 0.46 (0.06–0.74) 0.30 (scale not reliable–0.70)
Lumbar spine 0.56 (0.16–0.80) 0.58 (scale not reliable–0.83)
Pelvis 0.90 (0.78–0.96) 0.83 (0.52–0.93)
Long bones 0.35 (scale not reliable–0.66) 0.63 (0.10–0.85)
Skull 0.41 (0.01–0.70) 0.52 (scale not reliable–0.80)
Rib and other bones 0.79 (0.56–0.91) 0.56 (scale not reliable–0.82)
Whole skeleton 0.77 (0.45–0.91) 0.72 (0.34–0.88)
Table 2 Interobserver agreement
as demonstrated by ICC for
scoring WB-MRI for individual
body regions and the whole
skeleton
WB-MRI ICC between experienced observers
(95% confidence interval)
ICC between junior observers
(95% confidence interval)
Cervical spine 0.90 (0.79–0.96) 0.74 (0.38–0.89)
Thoracic spine 0.90 (0.78–0.96) 0.68 (0.25–0.86)
Lumbar spine 0.89 (0.75–0.95) 0.80 (0.53–0.92)
Pelvis 0.99 (0.97–0.99) 0.98 (0.95–0.99)
Long bones 0.92 (0.81–0.96) 0.89 (0.74–0.95)
Skull 0.89 (0.76–0.95) 0.72 (0.35–0.88)
Rib and other bones 0.92 (0.81–0.97) 0.91 (0.78–0.96)
Whole skeleton 0.98 (0.96–0.99) 0.95 (0.73–0.98)
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Statistical analyses were performed using IBM SPSS
Statistics for Windows Version 25.0 (SPSS Inc.). ICC
values less than 0.5 are considered to be indicative of poor
reliability, values between 0.5 and 0.75 indicate moderate
reliability, values between 0.75 and 0.9 indicate good reli-
ability, and values greater than 0.90 indicate excellent re-
liability [14]. With two observers, to detect the smallest
possible value of 0.5 for ICC, using a two-sided test, with
a pre-specified 5% significance level test (α = 0.05) and a
power of 80% (β = 0.2), the required sample size is
approximately 22 [15]. The median and interquartile
ranges (IQR) of the consensus observer scores on WB-
MRI were compared with those on WB-CT, and the
Wilcoxon signed-rank test was used to test the null hypoth-
esis that the average signed rank of the two samples is zero.
Spearman’s rank correlation coefficients were used to eval-
uate whether the WB-MRI and WB-CT scores of one ob-
server correlated with the analogous scores of the other
observer on a per-region and per-patient basis. A value of
p < 0.05 was taken to be statistically significant in all tests.
Fig. 1 Interobserver agreement forWB-CTandWB-MRI expressed as intraclass correlation coefficient with 95% confidence intervals between a pair of
experienced radiologists and between a pair of junior radiologists, respectively
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Results
A total of 22 patients with treatment-naïve symptomatic my-
eloma (mean age 61, range 36–72, 12 female and 10 male)
were included. (Please see supplemental information for
clinical details of the patient population.) A total of 154 body
regions were scored for the presence of disease on CT and
MRI. The interval between WB-CT and WB-MRI studies
ranged from 0 to 26 days (mean 3 days, median 0 days).
Mean bone marrow infiltration was 45% (range 15–80%).
The mean DLP for WB-CT studies was 426.7 mGy/cm.
Interobserver agreement
The first pair of experienced readers assessing WB-CT
showed good interobserver agreement for scoring across the
Fig. 2 A 50-year-old gentleman
with kappa light chain myeloma
and 20% clonal cells on trephine
bone marrow biopsy was found to
have focal lesions in the cervical
and lumbosacral spine, ribs and
long bones on WB-MRI by all
observers. The experienced ob-
servers detected additional small
deposits in the left parietal skull
vault (a) and in the spinous pro-
cess of T4 vertebra (b, solid ar-
row) on an axial b900 DWI im-
ages; the latter being more evident
on the b900 sagittal reformatted
images (c, arrow). These subtle
lesions were missed by the junior
observers, resulting in a discrep-
ancy in observer scores. The left
humeral and left rib lesions (b,
dotted arrows) were detected by
all observers
Table 3 Median and interquartile
ranges (IQR) for consensus ob-
server scores for WB-CT and
WB-MRI. Wilcoxon signed-rank
test (two-tailed) showed no sta-
tistically significant difference
between the scores for WB-CT
and WB-MRI
WB-CT CB-MRI
Median scores IQR Median scores IQR Z p value
Cervical spine 0 0–2 0 0–0 − 1.51 0.13
Thoracic spine 0 0–2 0 0–2 − 0.36 0.72
Lumbar spine 0 0–2 0 0–2 − 0.32 0.75
Pelvis 1.5 0–4.25 1 0–4 − 0.39 0.70
Long bones 0 0–0 0 0–3 − 2.56 0.01
Skull 0 0–0.5 0 0–0 − 0.53 0.60
Rib and other bones 0 0–4 0 0–4 − 0.68 0.50
Whole skeleton 5 0–13 4 1.5–8.25 − 0.42 0.67
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whole skeleton (ICC estimate 0.77, 95%CI 0.53–0.90). With
regard to individual body regions, the agreement was best in
the bony pelvis with an ICC estimate of 0.90 (95%CI 0.78–
0.96), which is interpreted as good to excellent; however,
agreement was poor to good in the rest of the body with
ICC estimates ranging from 0.35 to 0.79 with wide 95% con-
fidence intervals (Table 1). ForWB-MRI, interobserver agree-
ment (Table 2) was excellent in scoring for the whole skeleton
(ICC estimate 0.98, 95%CI 0.96–0.99).
Although WB-CTwas found to be rather reliable in rating
pelvic lesions, WB-MRI showed almost perfect reliability
with robust 95% confidence intervals (ICC estimate of 0.99,
95%CI 0.97–0.99). WB-MRI also demonstrated good to ex-
cellent reliability across all other individual body regions with
ICC estimates ranging from 0.90 to 0.92, all with narrow 95%
confidence intervals (Table 2). ICC estimates and their 95%
confidence intervals are illustrated in Fig. 1.
Interobserver agreement between less experienced ju-
nior radiologists showed similar trends. For WB-CT, there
was a moderate interobserver agreement for scoring
across the whole skeleton (ICC estimate 0.72, 95%CI
0.34–0.88). With regard to individual body regions, the
agreement was the best in the bony pelvis with an ICC
estimate of 0.83 (95%CI 0.52–0.93), which is interpreted
as moderate to excellent; however, agreement was poor to
at most good in the rest of the body with ICC estimates
ranging from 0.30 to 0.58 with wide 95% confidence in-
tervals (Table 1). For WB-MRI, interobserver agreement
(Table 2) was good in scoring for the whole skeleton (ICC
estimate 0.95, 95%CI 0.73–0.98) (Fig. 2). For inexperi-
enced observers, we should be cautious as although there
is a trend for better ICC on whole skeleton WB-MRI, the
confidence intervals do overlap.
Fig. 3 Marrow infiltration in
bilateral femora in a 67-year-old
male patient with IgG kappa my-
eloma and a high disease burden
of 70% clonal cells on bone mar-
row biopsy. Disease is occult on
axial CT (b) as there is no cortical
destruction. However, widespread
marrow disease is easily appre-
ciable on WB-MRI maximum in-
tensity projection (a, black ar-
rows), b = 900 s/mm2 (c, arrows)
axial images and ADC map (d,
arrows), as regions of low signal
intensities on the WB-DWI MIP
image and as foci of high signal
on the native b900 DWI image
Table 4 Correlation between consensus WB-CT and WB-MRI scores
for individual body regions and the whole skeleton, with p values for a
two-tailed test of the null hypothesis rho = 0
Region Correlation coefficient (Spearman’s rho) p value
Cervical spine 0.36 0.10
Thoracic spine 0.25 0.56
Lumbar spine 0.81 < 0.01
Pelvis 0.39 0.71
Long bones 0.58 < 0.01
Skull 0.33 0.13
Rib and other bones 0.61 < 0.01
Whole skeleton 0.61 < 0.01
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Observer scores for disease burden assessment
For all body regions and for the whole skeleton, median ob-
server scores for WB-CT and WB-MRI are not significantly
different from one another, as detailed in Table 3.
As listed in Table 4, there is a positive correlation between
all scores rated by WB-CT and by WB-MRI, which is statis-
tically significant in the lumbar spine, long bones, ribs and
other bones and the whole skeleton. Correlation is highest
for the lumbar spine (Spearman’s rho = 0.81, p < 0.01).
Correlation is lowest and statistically insignificant for the tho-
racic spine (Spearman’s rho = 0.25, p¸ = 0.56). There is a
moderate correlation for the whole skeleton (Spearman’s rho =
0.61) and the remaining individual body regions (Spearman’s
rho = 0.33 to 0.61).
Discussion
The study is the first to compare interobserver agreement be-
tweenWB-MRI andWB-CT. Higher interobserver agreement
of WB-MRI compared with WB-CTwas demonstrated across
the entire skeleton and for individual body regions by experi-
enced and junior radiologists. Although higher scores were
derived from WB-MRI compared with that from WB-CT for
disease detection in long bones, there was no difference in the
overall observer score. However, the study was limited by the
inclusion of patients with confirmed myeloma and a high
mean percentage marrow infiltration. The study therefore did
not include a significant number of patients with lower disease
burdens where MRI could be advantageous.
The clinical interpretation of whole-body cross-sectional
studies is based on essentially visual assessment of the graph-
ical representation of digital data, which is subject to varia-
tions due to observer experience, image interpretation and
reading conditions. Hence, the interobserver agreement can
be influenced by whether there is a distinct contrast between
the normal and abnormal that can be easily and readily detect-
ed by the human eye. Inconsistency in interpretation is exac-
erbated in modalities where the difference between normal
and abnormal is subtle, or when there is considerable overlap.
As with any diagnostic test, to reach a valid diagnosis and
judgement, it is desirable for the imaging used to assess my-
eloma to have a high degree of agreement. While agreement
does not imply accuracy, a test with poor interobserver agree-
ment cannot be reliably used in the clinical setting for the
management decision-making [16].
DWI provides information on marrow cellularity, which
has been shown to offer excellent visual contrast between
normal and infiltrated hypercellular marrow compared with
conventional MR sequences such as T1-weighted, short-tau
inversion recovery and contrast-enhanced sequences [12,
17–19].Moreover, CT has an inherent limitation in visualising
the bone marrow and can often only reveal the secondary
effects of myeloma on cortical and trabecular bone [5, 19],
and the differentiation between normal bone marrow and lytic
lesions is even more difficult in patients with generalised os-
teoporosis, which is often the case in myeloma patients, due to
systemic factors [20] and age. The improved lesion conspicu-
ity on MRI and in particular DWI, when compared with CT,
can explain the higher interobserver agreement of WB-MRI,
as illustrated in Fig. 3.
The challenges many centres face in providing WB-MRI
services are predominantly capacity issues. Although WB-
MRI has been shown to be well tolerated by patients with
myeloma in a tertiary referral centre [7], acutely unwell pa-
tients may not be able to tolerate WB-MRI scans which can
last for up to 45 min. Achieving faster scanning times is a
priority for WB-MRI researchers but until that is achieved,
shortened MRI protocols (i.e. spine and pelvis coverage only)
and WB-CT are reasonable alternatives [21]. The position of
WB-MRI is shifting from a state-of-the-art imaging technique
to standard practice in oncological imaging, for disease detec-
tion, characterisation and therapy response in multiple
myeloma.
Conclusion
WB-MRI is an increasingly deployed imaging technique in
cancer imaging. It can offer excellent interobserver agreement
in quantifying disease burden for the whole skeleton and
across any individual body region in myeloma patients.
Future larger-scale multi-centre studies are anticipated to pro-
vide further evidence to support this practice.
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